{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:12:30Z","timestamp":1791141150225,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bbcan.2025.189426","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T01:20:57Z","timestamp":1755739257000},"page":"189426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Integrating multi-omics proteomic approaches in deciphering the tumor microenvironment and therapeutic resistance mechanisms in prostate cancer"],"prefix":"10.1016","volume":"1880","author":[{"given":"Yutao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17\u201318","key":"10.1016\/j.bbcan.2025.189426_bb0005","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1101\/gad.315739.118","article-title":"Genetics and biology of prostate cancer","volume":"32","author":"Wang","year":"2018","journal-title":"Genes Dev."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189426_bb0010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","article-title":"High-risk prostate cancer-classification and therapy","volume":"11","author":"Chang","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5.5","key":"10.1016\/j.bbcan.2025.189426_bb0015","first-page":"583","article-title":"NCCN guidelines updates: Management of Prostate Cancer","volume":"17","author":"Mohler","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189426_bb0020","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.31860","article-title":"Oligometastatic prostate cancer: reality or figment of imagination?","volume":"125","author":"Foster","year":"2019","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189426_bb0025","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3348\/kjr.2018.19.5.819","article-title":"Prostate-specific membrane antigen PET imaging in prostate Cancer: opportunities and challenges","volume":"19","author":"Oh","year":"2018","journal-title":"Korean J. Radiol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189426_bb0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.eururo.2015.12.045","article-title":"Limitations of prostate-specific antigen testing after a prostate Cancer diagnosis","volume":"70","author":"Caram","year":"2016","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189426_bb0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0025-6196(12)61615-2","article-title":"Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy","volume":"69","author":"Ruckle","year":"1994","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189426_bb0040","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.urolonc.2009.11.003","article-title":"Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer","volume":"29","author":"Payne","year":"2011","journal-title":"Urol. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189426_bb0045","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.juro.2007.10.023","article-title":"Prostate specific antigen kinetics in the management of prostate cancer","volume":"179","author":"Sengupta","year":"2008","journal-title":"J. Urol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189426_bb0050","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc2351","article-title":"Prostate-specific antigen and prostate cancer: prediction, detection and monitoring","volume":"8","author":"Lilja","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189426_bb0055","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/14728222.2023.2293757","article-title":"Novel signatures of prostate cancer progression and therapeutic resistance","volume":"27","author":"Wang","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189426_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030904","article-title":"Profiling prostate cancer therapeutic resistance","volume":"19","author":"Wade","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189426_bb0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11912-017-0568-7","article-title":"Mechanisms of therapeutic resistance in prostate cancer","volume":"19","author":"Nakazawa","year":"2017","journal-title":"Curr. Oncol. Rep."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189426_bb0070","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189426_bb0075","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate Cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr. Rev."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189426_bb0080","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1249\/MSS.0000000000003095","article-title":"Resistance exercise training increases muscle mass and strength in prostate cancer patients on androgen deprivation therapy","volume":"55","author":"Houben","year":"2023","journal-title":"Med. Sci. Sports Exerc."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189426_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.10.006","article-title":"Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer","volume":"41","author":"Hawley","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189426_bb0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","article-title":"Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression","volume":"23","author":"Chen","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbcan.2025.189426_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216244","article-title":"Single-cell RNA sequencing reveals that HSD17B2 in cancer-associated fibroblasts promotes the development and progression of castration-resistant prostate cancer","volume":"566","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189426_bb0100","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175949","article-title":"Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts","volume":"134","author":"Zhang","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189426_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23116281","article-title":"From omics to multi-omics approaches for in-depth analysis of the molecular mechanisms of prostate Cancer","volume":"23","author":"Nevedomskaya","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189426_bb0110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-023-01393-9","article-title":"Integrative multi-omics and drug-response characterization of patient-derived prostate cancer primary cells","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"18","key":"10.1016\/j.bbcan.2025.189426_bb0115","doi-asserted-by":"crossref","first-page":"2305724","DOI":"10.1002\/advs.202305724","article-title":"Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity","volume":"11","author":"Bian","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189426_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2022.10.011","article-title":"FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer","volume":"40","author":"Han","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189426_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118376","article-title":"An overview of advances in multi-omics analysis in prostate cancer","volume":"260","author":"Zhang","year":"2020","journal-title":"Life Sci."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189426_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate Cancer: at the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"49","key":"10.1016\/j.bbcan.2025.189426_bb0135","doi-asserted-by":"crossref","first-page":"31189","DOI":"10.1073\/pnas.2017152117","article-title":"Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis","volume":"117","author":"Yi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189426_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115515","article-title":"AR-V7 in metastatic prostate Cancer: a strategy beyond redemption","volume":"22","author":"Sobhani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189426_bb0145","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189426_bb0150","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-20-1965","article-title":"KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate Cancer","volume":"81","author":"Gao","year":"2021","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189426_bb0155","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","article-title":"ATR inhibition induces CDK1-SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate Cancer","volume":"27","author":"Tang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189426_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176007","article-title":"Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer","volume":"957","author":"Yu","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"694","key":"10.1016\/j.bbcan.2025.189426_bb0165","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1126\/scitranslmed.ade5855","article-title":"Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer","volume":"15","author":"Wang","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189426_bb0170","doi-asserted-by":"crossref","first-page":"1133160","DOI":"10.3389\/fimmu.2023.1133160","article-title":"Identification of cancer-associated fibroblasts subtypes in prostate cancer","volume":"14","author":"Pan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189426_bb0175","doi-asserted-by":"crossref","first-page":"1412337","DOI":"10.3389\/fcell.2024.1412337","article-title":"Cancer-associated fibroblasts and prostate cancer stem cells: crosstalk mechanisms and implications for disease progression","volume":"12","author":"Chen","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189426_bb0180","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1186\/s12967-024-05413-2","article-title":"CAFs gene signatures predict outcomes in breast and prostate tumor patients","volume":"22","author":"Talia","year":"2024","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189426_bb0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cjp2.205","article-title":"A distinct repertoire of cancer-associated fibroblasts is enriched in cribriform prostate cancer","volume":"7","author":"Hesterberg","year":"2021","journal-title":"J. Pathol. Clin. Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189426_bb0190","doi-asserted-by":"crossref","first-page":"2303894","DOI":"10.1002\/advs.202303894","article-title":"Taurine inhibits ferroptosis mediated by the crosstalk between tumor cells and tumor-associated macrophages in prostate cancer","volume":"11","author":"Xiao","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189426_bb0195","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/ERC-15-0123","article-title":"Regulation of vascular endothelial growth factor in prostate cancer","volume":"22","author":"Brot","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"issue":"23","key":"10.1016\/j.bbcan.2025.189426_bb0200","doi-asserted-by":"crossref","first-page":"10921","DOI":"10.1158\/0008-5472.CAN-05-1809","article-title":"Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity","volume":"65","author":"Kitagawa","year":"2005","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189426_bb0205","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/mc.23157","article-title":"Exosomes secreted by prostate cancer cells under hypoxia promote matrix metalloproteinases activity at pre-metastatic niches","volume":"59","author":"Deep","year":"2020","journal-title":"Mol. Carcinog."},{"issue":"1 Pt 3","key":"10.1016\/j.bbcan.2025.189426_bb0210","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.gene.2015.11.005","article-title":"Kindlin-2 promotes invasiveness of prostate cancer cells via NF-\u03baB-dependent upregulation of matrix metalloproteinases","volume":"576","author":"Yang","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.bbcan.2025.189426_bb0215","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijbiomac.2022.02.094","article-title":"Transforming growth factor-beta (TGF-\u03b2) in prostate cancer: a dual function mediator?","volume":"206","author":"Mirzaei","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189426_bb0220","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.eururo.2017.12.008","article-title":"Efficacy against human prostate Cancer by prostate-specific membrane antigen-specific, transforming growth factor-\u03b2 insensitive genetically targeted CD8(+) T-cells derived from patients with metastatic castrate-resistant disease","volume":"73","author":"Zhang","year":"2018","journal-title":"Eur. Urol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189426_bb0225","article-title":"Impacts of Interleukin-10 promoter genotypes on prostate cancer","volume":"14","author":"Chin","year":"2024","journal-title":"Life (Basel)"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189426_bb0230","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ejca.2006.11.003","article-title":"Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study","volume":"43","author":"Eder","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"18","key":"10.1016\/j.bbcan.2025.189426_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189926","article-title":"Angiogenesis and anti-Angiogenic treatment in prostate cancer: mechanisms of action and molecular targets","volume":"22","author":"Ioannidou","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"Pt B","key":"10.1016\/j.bbcan.2025.189426_bb0240","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.ijbiomac.2022.10.014","article-title":"HIF1\u03b1 lactylation enhances KIAA1199 transcription to promote angiogenesis and vasculogenic mimicry in prostate cancer","volume":"222","author":"Luo","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189426_bb0245","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11934-023-01159-4","article-title":"Metastasis-directed therapy for Oligometastatic castration-sensitive prostate Cancer: an alternative to ADT?","volume":"24","author":"Cahill","year":"2023","journal-title":"Curr. Urol. Rep."},{"key":"10.1016\/j.bbcan.2025.189426_bb0250","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2022.01.015","article-title":"Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer","volume":"530","author":"Kang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189426_bb0255","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2147\/OTT.S98807","article-title":"Bioinformatics analysis of differentially expressed proteins in prostate cancer based on proteomics data","volume":"9","author":"Chen","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189426_bb0260","doi-asserted-by":"crossref","first-page":"99630","DOI":"10.1371\/journal.pone.0099630","article-title":"Effects of eicosapentaenoic acid and docosahexaenoic acid on prostate cancer cell migration and invasion induced by tumor-associated macrophages","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189426_bb0265","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2326-6066.CIR-14-0036","article-title":"Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models","volume":"3","author":"Shen","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189426_bb0270","first-page":"2037","article-title":"Immuno-PET imaging of VEGFR-2 expression in prostate cancer with (89)Zr-labeled ramucirumab","volume":"9","author":"Li","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189426_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105176","article-title":"New N-(1,3,4-thiadiazol-2-yl)furan-2-carboxamide derivatives as potential inhibitors of the VEGFR-2","volume":"115","author":"Hekal","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"695","key":"10.1016\/j.bbcan.2025.189426_bb0280","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.1126\/scitranslmed.adf6724","article-title":"Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies","volume":"15","author":"Shi","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189426_bb0285","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"Mateo","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"6320","key":"10.1016\/j.bbcan.2025.189426_bb0290","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189426_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/biom11020247","article-title":"Post-translational modifications that drive prostate Cancer progression","volume":"11","author":"Samar\u017eija","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbcan.2025.189426_bb0300","doi-asserted-by":"crossref","first-page":"17768","DOI":"10.7717\/peerj.17768","article-title":"The role of protein post-translational modifications in prostate cancer","volume":"12","author":"Hao","year":"2024","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189426_bb0305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/jcb.10708","article-title":"Fatty acid synthase: a metabolic oncogene in prostate cancer?","volume":"91","author":"Baron","year":"2004","journal-title":"J. Cell. Biochem."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189426_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112447","article-title":"Deciphering fatty acid synthase inhibition-triggered metabolic flexibility in prostate Cancer cells through untargeted metabolomics","volume":"9","author":"Oh","year":"2020","journal-title":"Cells"},{"issue":"3\u20134","key":"10.1016\/j.bbcan.2025.189426_bb0315","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10555-011-9299-7","article-title":"Polyunsaturated fatty acid metabolism in prostate cancer","volume":"30","author":"Berquin","year":"2011","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbcan.2025.189426_bb0320","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3389\/fonc.2020.01510","article-title":"Targeting SREBP-2-regulated mevalonate metabolism for Cancer therapy","volume":"10","author":"Xue","year":"2020","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189426_bb0325","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1158\/0008-5472.CAN-2148-2","article-title":"Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence","volume":"64","author":"Ettinger","year":"2004","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189426_bb0330","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.bbcan.2025.189426_bb0335","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1002\/cam4.3108","article-title":"Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: a meta-analysis","volume":"9","author":"Li","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbcan.2025.189426_bb0340","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189426_bb0345","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189426_bb0350","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ijc.31877","article-title":"Sertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain","volume":"144","author":"Hu","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189426_bb0355","first-page":"885","article-title":"Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer","volume":"99","author":"Yeh","year":"2000","journal-title":"J. Formos. Med. Assoc."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189426_bb0360","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1042\/CS20160026","article-title":"Prostate cancer, PI3K, PTEN and prognosis","volume":"131","author":"Wise","year":"2017","journal-title":"Clin. Sci. (Lond.)"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189426_bb0365","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41588-022-01045-8","article-title":"HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer","volume":"54","author":"Lu","year":"2022","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189426_bb0370","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/mc.23214","article-title":"Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer","volume":"59","author":"Shankar","year":"2020","journal-title":"Mol. Carcinog."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189426_bb0375","first-page":"80","article-title":"Environmental exposures and Cancer risk: a comprehensive review","volume":"2","author":"Ajayi","year":"2024","journal-title":"Medinformatics"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189426_bb0380","doi-asserted-by":"crossref","first-page":"20","DOI":"10.47852\/bonviewMEDIN32021546","article-title":"The importance of KRAS quantification for a clinicopathological characterization in colorectal cancer patients","volume":"1","author":"Bratei","year":"2023","journal-title":"Medinformatics"},{"key":"10.1016\/j.bbcan.2025.189426_bb0385","doi-asserted-by":"crossref","unstructured":"Sinha, A., The Proteogenomic landscape of curable prostate Cancer. Cancer Cell, 2019. 35(3): p. 414\u2013427 6.","DOI":"10.1016\/j.ccell.2019.02.005"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189426_bb0390","doi-asserted-by":"crossref","first-page":"273","DOI":"10.21873\/cgp.20132","article-title":"Comparative proteome profiling and mutant protein identification in metastatic prostate cancer cells by quantitative mass spectrometry-based Proteogenomics","volume":"16","author":"Kwon","year":"2019","journal-title":"Cancer Genomics Proteomics"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189426_bb0395","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s43018-024-00820-2","article-title":"Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers","volume":"5","author":"Dong","year":"2024","journal-title":"Nat. Cancer."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189426_bb0400","first-page":"664","article-title":"Re: the Proteogenomic landscape of curable prostate Cancer","volume":"202","author":"Atala","year":"2019","journal-title":"J. Urol."},{"key":"10.1016\/j.bbcan.2025.189426_bb0405","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ctrv.2015.12.003","article-title":"AR-V7 and prostate cancer: the watershed for treatment selection?","volume":"43","author":"Ciccarese","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189426_bb0410","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41571-018-0085-0","article-title":"Alternative splicing in prostate cancer","volume":"15","author":"Paschalis","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189426_bb0415","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.eururo.2015.10.053","article-title":"The proteome of primary prostate cancer","volume":"69","author":"Iglesias-Gato","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2025.189426_bb0420","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fonc.2017.00267","article-title":"Quantitative mass spectrometry-based proteomic profiling for precision medicine in prostate cancer","volume":"7","author":"Flores-Morales","year":"2017","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189426_bb0425","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s41467-018-03573-6","article-title":"Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression","volume":"9","author":"Latonen","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189426_bb0430","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12014-025-09534-8","article-title":"Histology-resolved proteomics reveals distinct tumor and stromal profiles in low- and high-grade prostate cancer","volume":"22","author":"Hunt","year":"2025","journal-title":"Clin. Proteomics"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189426_bb0435","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00216-024-05178-z","article-title":"Spatial MS multiomics on clinical prostate cancer tissues","volume":"416","author":"Truong","year":"2024","journal-title":"Anal. Bioanal. Chem."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189426_bb0440","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/pros.23836","article-title":"IL-8 protects prostate cancer cells from GSK-3\u03b2-induced oxidative stress by activating the mTOR signaling pathway","volume":"79","author":"Sun","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.bbcan.2025.189426_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2021.01.106","article-title":"TPX2 mediates prostate cancer epithelial-mesenchymal transition through CDK1 regulated phosphorylation of ERK\/GSK3\u03b2\/SNAIL pathway","volume":"546","author":"Zhang","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189426_bb0450","doi-asserted-by":"crossref","DOI":"10.3390\/biom11071009","article-title":"Protein phosphorylation in Cancer: role of nitric oxide signaling pathway","volume":"11","author":"Liu","year":"2021","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189426_bb0455","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41419-023-05773-5","article-title":"Post-transcriptional modification of m(6)a methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189426_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216464","article-title":"SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrest","volume":"579","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189426_bb0465","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12885-017-3256-y","article-title":"Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression","volume":"17","author":"Ngollo","year":"2017","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1016\/j.bbcan.2025.189426_bb0470","doi-asserted-by":"crossref","first-page":"2101458","DOI":"10.1002\/advs.202101458","article-title":"Co-targeting Plk1 and DNMT3a in advanced prostate cancer","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv. Sci. (Weinh)"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189426_bb0475","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1210\/en.2011-1056","article-title":"Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models","volume":"152","author":"Gravina","year":"2011","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189426_bb0480","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/s41467-021-22163-7","article-title":"SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis","volume":"12","author":"Shangguan","year":"2021","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189426_bb0485","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23095269","article-title":"Exploiting the metabolic consequences of PTEN loss and Akt\/hexokinase 2 Hyperactivation in prostate Cancer: a new role for \u03b4-Tocotrienol","volume":"23","author":"Fontana","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T21:21:38Z","timestamp":1758144098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25001684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0304419X25001684"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189426","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating multi-omics proteomic approaches in deciphering the tumor microenvironment and therapeutic resistance mechanisms in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189426","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189426"}}